For more information

Dept. of Dermatology
Mail Code: L468R
Oregon Health & Science University
3181 SW Sam Jackson Park Rd.
Portland, OR 97239

Office: (503) 418-4273
Fax: (503) 418-4266

info(at)
montagnasymposium.org

Molly Kulesz-Martin, Ph.D.
Symposium Director

David Norris, M.D.
Jackie Bickenbach, Ph.D.
Symposium Directors Emeriti

Looking for meeting photos and updates? Follow the Montagna Symposium on Facebook
Facebook

Preliminary Program
Talk titles and schedule subject to change

THURSDAY, OCTOBER 12, 2017
Registration & check-in 4pm, Opening reception 6pm, Keynote talk 7pm

Keynote Talk
Speaker TBA

FRIDAY, OCTOBER 13, 2017
Breakfast 7–8am, Talks 8am–5:15pm, Poster session 5:15–7pm

Session (1): Genes—John McGrath, M.D., Session Chair
Digital code—Genetically defined diagnosis and therapy

Diagnosis
Gene hunting. John McGrath, M.D., London, UK
Molecular genetics of cutaneous neoplasms. Boris Bastian, M.D., Ph.D., San Francisco, CA
DNA variations. Raymond Cho, M.D., Ph.D., San Francisco
Pharmacogenomics. Amy Foulkes, Ph.D., Manchester, UK

Therapy
Spliceosome-mediated RNA trans-splicing (SMaRT). Johann Bauer, M.D., Salzburg, Austria
Editing. Mark Osborn, Ph.D., Minneapolis, MN

Session (2): Cells—Dan Kaplan, M.D., Ph.D., Session Chair
Biobricks—Cells as living medications

Stromal cells
Keratinocyte cells (KCs). Paola di Meglio, Ph.D., London, UK
Mesenchymal stem cells (MSCs). Markus Frank, M.D., Boston, MA
Induced pluripotent stem cells (iPS). Tony Oro, M.D., Ph.D., Stanford, CA

Immune cells
Hematopoietic stem cells (HSCs). Jakub Tolar, M.D., Ph.D., Minneapolis, MN
Chimeric autoantibody receptor (CAAR)-T cells: Precision medicine for autoantibody-mediated disease. Aimee S. Payne, M.D., Ph.D., Philadelphia, PA
T cell-mediated immune responses to external stimuli: Proposal of inducible skin-associated lymphoid tissue (iSALT). Kenji Kabashima, M.D., Ph.D., Kyoto, Japan
Immune crosstalk. Daniel Kaplan, M.D., Ph.D, Pittsburgh, PA

SATURDAY, OCTOBER 14, 2017
Breakfast 7–8am, Talks 8am–12pm, Optional hike or other excursion 1–5pm, Dinner 6–8:30pm

Session (3): Tissues—Johann Bauer, M.D., Session Chair
Bioplastics—Engineering new skin

Grafts
Recessive dystrophic epidermolysis bullosa (RDEB). M. Peter Marinkovich, M.D., Stanford, CA
Junctional epidermolysis bullosa (JEB) grafting. Johann Bauer, M.D., Salzburg, Austria
Combined cell and gene therapy of junctional epidermolysis bullosa (JEB) shed light on human epidermal stem cells. Michele De Luca, M.D., Modena, Italy

Nanobiotechnology
3D Printed Skin Electronics. Michael McAlpine, Ph.D., Minneapolis, MN

Banquet Speaker:
Douglas R. Lowy, M.D., Washington, DC

SUNDAY, OCTOBER 15, 2017
Breakfast 7–8am, Talks 8am–5pm, Dinner 6–8pm

Session (4): Devices—Sancy Leachman, M.D., Ph.D., Session Chair
Living Software—Big data, bigger picture

Knowhow
From skin histology to 3D EM. Joe Gray, Ph.D., Portland, OR
Hyperspectral, confocal, dermatoscopic imaging. Alexander Witkowski, M.D., Ph.D., Krakow, Poland

Data amplification
MoleMapper and more. Sancy Leachman, M.D., Ph.D., Portland, OR
Dermatologist-level classification of skin cancer with deep neural networks. Andre Esteva, Ph.D. Candidate, Stanford, CA
Mobile apps and Research Kit. Tracy Petrie, Ph.D., Portland, OR

Session (5): People—Amy Paller, M.D., Session Chair
Patients—Adaptive clinical trials

Alopecia areata. Angela Christiano, Ph.D., New York, NY
Ichthyosis. Amy Paller, M.D., Chicago, IL
Vascular malformations. Joyce Teng, M.D., Ph.D., Stanford, CA
Melanoma. Roger Lo, M.D., PhD., Los Angeles, CA

MONDAY, OCTOBER 16, 2017
Breakfast, 7:30–8:30am, Airport bus departure, 9am

Funding for this conference was made possible (in part) by (2 R13AR009431-51) from the National Institute Of Arthritis and Musculoskeletal And Skin Diseases (NIAMS) and all cofunding support provided the National Institute On Aging (NIA). The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.